Chesapeake Corporate Advisors

OCTOBER 24, 2022

(“Rendia”), a provider of subscription-based point-of-care engagement software and content for eye care practitioners, in its sale to PatientPoint ® (“PatientPoint”), provider of an industry-leading, tech-enabled point-of-care network that engages healthcare providers and patients across 20 medical specialties.

Advisory 52

Advisory Investment Banking Corporation Healthcare 52

The Deal

OCTOBER 2, 2023

Enovix, which had a roughly $2 billion market capitalization as of Wednesday’s close, is working to improve the current battery technology that is used widely in consumer devices such as mobile phones. The company is partnering with Android phone makers including Xiaomi Corp. and Lenovo Group Ltd.

Manufacturing 69

Manufacturing Electronics IT Investors 69

Focus Investment Banking

APRIL 1, 2024

All PPM organizations, including those in ENT & allergy, are designed to acquire, operate, and grow medical practices. Leveraging scale and knowing how to negotiate better rates with payors. Making day-to-day operations more efficient.

Private Equity 52

Private Equity Equities Investment Negotiation 52

Cooley M&A

FEBRUARY 8, 2018

Ideally, the revesting provisions are structured to provide key employees long-term capital gains treatment on any deferred payments (compared to the ordinary income attributed to vested options or restricted stock units cashed out at closing). The typical revesting period for these arrangements is 24 to 36 months. million to $84.4

M&A 52

M&A Mergers and Acquisitions Mergers Negotiation 52

Devensoft

AUGUST 22, 2023

Properly valuing a company involved in an M&A transaction allows stakeholders to make informed decisions and negotiate effectively. The Enterprise Value Calculator will then generate a valuation range, providing you with a foundation for negotiations and decision-making.

M&A 52

M&A Valuation Utilities Mergers and Acquisitions 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JUNE 10, 2020

At the most basic level, a buyer wants to understand two things: (1) is there an unmet medical need such that the company’s development-stage product will substantially improve the quality of care, and (2) is there sufficient exclusivity to allow commercialization of the product. Marketing the opportunity and other process considerations.

M&A 40

M&A Medical Acquisitions Business 40

Focus Investment Banking

MARCH 28, 2024

The reasoning is simply that, with lower interest rates, a buyer will be able to pay more for the PPM asset as their cost of capital is lower and lending requirements are more flexible. Investors tell us that they are waiting for more clarity on rates before going to market.

Private Equity 52

Private Equity Equities Valuation Acquisitions 52

Cooley M&A

JANUARY 24, 2020

Thereafter, plaintiffs’ counsel often demands a “mootness fee” (for the alleged benefit conferred by the supplemental disclosures), over which the parties can negotiate or litigate, if necessary.

M&A 40

M&A Mergers and Acquisitions Mergers Business 40

How2Exit

OCTOBER 7, 2024

Meanwhile, the Income Approach involves evaluating a company’s cash flow against perceived risks, utilizing methods like capitalization of earnings and discounted cash flow models. By employing these strategies, buyers move beyond mere negotiation, positioning themselves as savvy operators in an ever-evolving market.

Business 130

Business Mergers and Acquisitions Valuation Acquisitions 130

Software Equity Group

JANUARY 22, 2024

In this post, we’ll offer further insights into what’s driving the need for healthcare SaaS solutions and how business owners can capitalize on heightened activity in healthcare M&A. For these reasons and more, healthcare SaaS businesses have never been in a better position to negotiate a potential M&A transaction.

Healthcare 52

Healthcare M&A Valuation Medical 52

Software Equity Group

JANUARY 22, 2024

In this post, we’ll offer further insights into what’s driving the need for healthcare SaaS solutions and how business owners can capitalize on heightened activity in healthcare M&A. For these reasons and more, healthcare SaaS businesses have never been in a better position to negotiate a potential M&A transaction.

Healthcare 52

Healthcare M&A Valuation Medical 52

Cleary M&A and Corporate Governance Watch

MARCH 29, 2023

However, we expect that there will be lots of negotiating over the fiscal 2024 budget, so one or more of these proposals may find their way into the final budget. President Biden has also proposed applying ordinary income tax rates to the capital gains and qualified dividends of taxpayers with taxable income of more than $1.0

Accountant 52

Accountant Medical Investment Funds 52

Cooley M&A

JANUARY 25, 2024

Acquirers must be prepared for potential litigation domestically and internationally, and for more detailed negotiations over regulatory and interim operating covenants. In addition, acquirers’ appetite for mega-deals may continue to be more suppressed, and acquirers may pivot to smaller M&A opportunities.

M&A 52

M&A Mergers and Acquisitions Investment Government 52

Cooley M&A

JANUARY 25, 2023

Some sponsors, while unable to present compelling take-private proposals to targets, have deployed capital in private investments in public equity (PIPEs) of public targets, marketing these investments as both a vote of confidence for the incumbent board and much-needed liquidity to help the target weather the downturn.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 20, 2022

Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years. intensity dealmaking, as life sciences companies sought to deploy capital and keep pace in an environment of record growth. In fact, COVID?19’s

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 22, 2025

That said, some industry participants still looked to capitalize on anticipated vulnerabilities in their competitors pipelines with meaningful M&A bets such as Eli Lillys $2.3 By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Mergers and Inquisitions

MARCH 19, 2025

Or a venture capital investment into a direct-to-consumer brand seeking to disrupt the market for eyewear or electric shavers. Modest CapEx Requirements If you look at Damodarans data on capital intensity by sector , certain verticals were below the average 4 5% Net CapEx / Sales reported by U.S.

Private Equity 59

Private Equity Retail Equities Mergers and Acquisitions 59